Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20690392 | 1.00 | NPSR1 (0.33) | NPSR1MEN1KMT2AGABRR1MMP2 | |
| SCHEMBL21576490 | 1.00 | NPSR1 (0.33) | NPSR1MEN1KMT2AGABRR1MMP2 | |
| Hydrochloric Acid SCHEMBL21570151 | 0.98 | NPSR1 (0.32) | NPSR1MEN1KMT2AGABRR1MMP2 | |
| Trifluoroacetic Acid SCHEMBL31196404 | 0.87 | — | — | |
| SCHEMBL30234161 | 0.86 | ATM (0.33) | ALDH1A1 | |
| SCHEMBL17064244 | 0.84 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL21496929 | 0.84 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2340412 | 0.84 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2340414 | 0.84 | NPSR1 (0.33) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL17062254 | 0.82 | NPSR1 (0.32) | NPSR1MEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPSR1 3277/4885MEN1 2199/4885KMT2A 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.